[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642539":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":64,"collaborators":25,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":25,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":92,"whyStopped":25,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Universidad Nacional Autonoma de Honduras","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Furosemide","EXPERIMENTAL","Every 24 hours starting at 12 hours postpartum until discharge",[13],"Drug: Furosemide",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Folic acid, 5 mg per day Every 24 hours starting at 12 hours postpartum until discharge",[19],"Drug: Folic Acid 5 MG",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Furosemide 40 mg tablet, oral, once daily. First dose administered exactly 12 hours postpartum (vaginal or cesarean). Continued every 24 hours until hospital discharge, defined as blood pressure \\\u003C140\u002F90 mmHg for ≥24 hours without rescue antihypertensives. Population: severe preeclampsia (BP ≥160\u002F110 mmHg OR lower BP with thrombocytopenia, hepatic dysfunction, renal insufficiency, pulmonary edema, or cerebral\u002Fvisual symptoms). Setting: postpartum wards in two public hospitals in Honduras. Rescue medication: labetalol or hydralazine for BP \\>160\u002F110 mmHg, deferred ≥2 hours after study drug when possible. Placebo comparator: folic acid 5 mg orally every 24 hours, identical appearance, packaging, and schedule. What distinguishes this intervention: first postpartum diuretic trial in severe preeclampsia with hospital length of stay as primary endpoint in a low-middle income country setting.",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Folic Acid 5 MG","Folic acid 5 mg oral once daily, starting at exactly 12 hours postpartum until hospital discharge (BP \\\u003C140\u002F90 mmHg for ≥24 hours without rescue drugs). Population: severe preeclampsia. Setting: public hospitals, Honduras. Rescue: labetalor hydralazine for BP \\>160\u002F110 mmHg, deferred ≥2 hours post-dose. Active comparator: furosemide 40 mg oral, identical appearance and schedule. Folic acid has no antihypertensive or diuretic effects in postpartum women, serving as an appropriate placebo.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Ricardo A. Gutierrez-Ramirez, MD, MSc","CONTACT","+50497546940","ricardo.gutierrez@unah.edu.hn",[37],{"facility":38,"status":25,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Hospital Escuela","Tegucigalpa","Francisco Morazán Department","11101","Honduras","HN",{"type":45,"coordinates":46},"Point",[47,48],-87.20681,14.0818,{"lat":48,"lon":47},[51,54,57,59,62],{"name":52,"role":33,"phone":53,"phoneExt":25,"email":35},"Ricardo A. Gurierrez Ramirez, MD, MSc.","97546940",{"name":55,"role":56,"phone":25,"phoneExt":25,"email":25},"Francisco J. Salgado Turcios, MD","PRINCIPAL_INVESTIGATOR",{"name":58,"role":56,"phone":25,"phoneExt":25,"email":25},"Andrés F. García Mejía, MD",{"name":60,"role":61,"phone":25,"phoneExt":25,"email":25},"Doria A. Carrasco, MD, MSc.","SUB_INVESTIGATOR",{"name":63,"role":61,"phone":25,"phoneExt":25,"email":25},"Sobeyda Lopez, MD",{"type":56,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Ricardo A Gutierrez Ramirez, MD, MSc, FACOG","Research Coordinator","100642539","phase-2-furosemide-vs-placebo-in-severe-preeclampsia-postpartum-100642539",false,"NCT07648251","Furosemide vs Placebo in Severe Preeclampsia Postpartum","Furosemide Oral Versus Placebo for Reduction of Hospital Length of Stay in Postpartum Women With Severe Preeclampsia: A Double-Blind, Randomized Controlled Trial","FUROPE","Inclusion Criteria:\n\n* Signed informed consent (assent for minors 14-17 years with parental\u002Fguardian consent)\n* Confirmed severe preeclampsia (BP ≥160\u002F110 mmHg, or lower BP with thrombocytopenia, hepatic dysfunction, renal insufficiency, pulmonary edema, or cerebral\u002Fvisual symptoms)\n* Postpartum (12-24 hours after delivery, vaginal or cesarean)\n* Hemodynamically stable (no vasopressors for ≥6 hours)\n* Preserved diuresis (\\>30 mL\u002Fhour for ≥6 hours)\n* Serum creatinine \\\u003C0.8 mg\u002FdL\n\nExclusion Criteria:\n\n* Current or chronic diuretic use (before or during pregnancy)\n* Known allergy to sulfonamides or furosemide\n* Active febrile illness\n* Known chronic kidney disease (eGFR \\\u003C60 mL\u002Fmin\u002F1.73m²)\n* Participation in another interventional trial\n* Pregnancy (current - not applicable postpartum, but excludes undiagnosed concurrent pregnancy)","FEMALE","14 Years","49 Years",{"count":79,"type":80},186,"ESTIMATED","INTERVENTIONAL",[83],"PHASE2","This randomized, double-blind, placebo-controlled trial evaluates whether oral furosemide 40 mg, initiated 12 hours postpartum, reduces hospital length of stay compared to placebo (folic acid 5 mg) in postpartum women with severe preeclampsia. Secondary outcomes include need for rescue antihypertensive medications, weight reduction, and metabolic safety (hypokalemia, renal function). A total of 186 participants (93 per arm) will be enrolled across two hospitals in Honduras.",[86],"Severe Preeclampsia",[88,9,89,90,91],"Preeclampsia","Postpartum","Hypertension","Length of Stay","NOT_YET_RECRUITING","2026-06-09",{"date":95,"type":96},"2026-06-15","ACTUAL",{"date":95,"type":80},{"date":99,"type":80},"2027-01-15",{"name":5,"class":6},1]